RALEIGH, N.C., Oct. 14, 2024 /PRNewswire/ — Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care therapies, announced that the U.S. Food and Drug…Original Article
FDA Approves Imuldosa (ustekinumab-srlf), a Biosimilar to Stelara
